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Introduction
Total knee arthroplasty (TKA) is usually performed in the setting of  an enhanced recovery protocol. TKA may be 
associated with severe postoperative pain that may hamper early mobilisation. Therefore, adequate pain relief  is 
an essential part of  enhanced recovery. In many centres, local infiltration analgesia (LIA) in combination with oral 
analgesics has been introduced as the preferred method of  postoperative analgesia because it combines adequate 
analgesia with a minimum of  side effects (1, 2). LIA protocols may vary with regard to dose and additives but are 
characterised by local infiltration of  the tissues surrounding the knee joint with a long-acting local anaesthetic (LA), 
such as ropivacaine.
Total knee arthroplasty can be performed with or without the use of  a tourniquet. When the LIA mixture is infiltrated 
in the absence of  a tourniquet, systemic absorption will commence immediately. By contrast, in case of  an inflated 
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Abstract
Objective: Local infiltration analgesia (LIA) with ropivacaine is increasingly used to provide postoperative analgesia after total knee arthroplasty 
(TKA). TKA may be performed with or without the use of  a tourniquet. The absence of  local blood flow when infiltrating local anaesthesia 
below an inflated tourniquet may affect the rate of  systemic absorption, and this may have an effect on the duration and intensity of  analgesia 
as compared with LIA without the use of  a tourniquet. The aim of  the present study was to investigate the influence of  tourniquet use during 
surgery on the time to first request (TTFR) of  opioids and opioid consumption.
Methods: Two historical time-based cohorts (one with and one without tourniquet during surgery) of  300 patients underwent primary TKA 
under spinal anaesthesia and received LIA to provide postoperative analgesia. The cohorts were compared for TTFR of  opioids and opioid 
consumption.
Results: TTFR did not significantly differ between the tourniquet and non-tourniquet groups with a median (25th-75th percentile) of  240 (102-
651) and 282 (100-720) min, respectively. The median (25th-75th percentile) oxycodone use was higher in the tourniquet group with 50 (20-90) 
versus 40 (10-77.5) mg (p=0.01).
Conclusion: There was no difference in the time to first opioid consumption, suggesting that the presence of  an inflated tourniquet during 
local anaesthetic injection does not alter systemic absorption sufficiently to affect the duration of  analgesia. However, the use of  a tourniquet was 
associated with a higher opioid consumption, which is most likely caused by pain resulting from the tourniquet itself.
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Original Article
Regional Anaesthesia
The material has been presented in part as an e-poster at the 36th Annual ESRA meeting, September 2017, Lugano, Switzerland; abstracts of  this meeting have been published in Regional 
Anesthesia and Pain Medicine 2017; 42: Supplement 1.
107
tourniquet, systemic absorption will be delayed until the tour-
niquet is deflated, and local blood flow is restored. On the other 
hand, after deflation of  a tourniquet, there will be a period of  
hyperaemia with a concomitant increase in systemic absorp-
tion. It is not known if  these differences in systemic absorption 
with or without tourniquet alter the pharmacokinetic profile of  
LIA sufficiently to affect the duration of  analgesia.
Until recently, TKA was performed with the use of  a tour-
niquet in our hospital, and LIA was performed for postop-
erative pain relief. The perceived advantages of  a tourniquet 
are a dry surgical field and reduced intraoperative blood loss. 
However, the use of  a tourniquet has become the subject of  
discussion. In two meta-analysis studies, Zhang et al. (3) and 
Tai et al. (4) showed that total blood loss is not affected by 
tourniquet use, but it does increase the risk of  thromboem-
bolic events and might even hinder early postoperative reha-
bilitation. Based on these results, our standard practice has 
recently been changed to performing TKA without the use of  
a tourniquet. The purpose of  this cohort study was to inves-
tigate if  the presence or absence of  an intraoperative tourni-
quet affects the duration of  LIA.
Methods
The study protocol was approved by the hospital’s investiga-
tional review board. The medical research and ethics com-
mittee of  Slotervaart Hospital and Reade, Amsterdam, The 
Netherlands reviewed the study on June 7, 2017 and deter-
mined, based on the Dutch Medical Research Involving Hu-
man Subjects Act, that the research activities described meet 
the requirements for exemption from ethical committee re-
view (Notification of  exemption U/17.083/P1733).
Patient demographics, procedure characteristics, opioid con-
sumption and use of  analgesics from 600 patients were extract-
ed from the patient data management system. In mid-2016, 
our standard surgical procedure for primary TKA changed 
from perioperative tourniquet use to surgery without the use of  
a tourniquet. The tourniquet cohort (group T) comprised the 
last 300 patients who underwent primary TKA with periop-
erative tourniquet use before protocol change. The non-tour-
niquet cohort (group NT) included the first 300 patients who 
underwent primary TKA after protocol change. Patients who 
were not treated according to the standard surgical procedure 
and perioperative protocol for the time-period in which they 
underwent surgery were excluded from the study.
Procedure
In our hospital, TKA is performed according to a standard 
protocol, detailing the anaesthetic and surgical procedure, 
perioperative pain treatment and rehabilitation and discharge 
criteria. All patients receive spinal anaesthesia with a 0.5% 10 
mg hyperbaric bupivacaine in the sitting position. Patients are 
turned into the lateral decubitus position for 20 min with the 
side of  surgery dependent to achieve a predominantly unilat-
eral block after bupivacaine injection. Upon request, patients 
receive conscious sedation with propofol (1-4 mg kg−1 h−1) 
during surgery.
In group T, a pneumatic tourniquet is placed on the patient’s 
thigh and automatically inflated to 50 mm Hg above systolic 
blood pressure. In group NT, no tourniquet is used. All pa-
tients receive LIA after the placement of  implants and before 
wound closure. The posterior and anterior knee capsules are 
infiltrated with 0.2% 100 mL and 50 mL ropivacaine+5 µg 
mL−1 epinephrine, respectively. The subcutaneous tissue is in-
filtrated with 0.2% 50 mL ropivacaine without epinephrine. 
All patients receive an i.v. bolus of  10 mg kg−1 tranexamic acid 
with a maximum of  1000 mg. This dose is administered just 
before tourniquet release in group T. In group NT, tranexam-
ic acid is administered in the anaesthetic room before the start 
of  surgery. All patients receive a compression bandage before 
transfer to the recovery room after wound closure.
Standard oral multimodal analgesia includes 1000 mg parac-
etamol q.i.d., 90 mg etoricoxib once daily and 600 mg b.i.d. 
or 300 mg gabapentin if  >60 years old. Pain is evaluated with 
a Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 
(worst pain imaginable). NRS scores are recorded by a nurse 
at least once during each 8-hour shift on the orthopaedic 
ward. In addition, patients are instructed to contact the nurs-
es when pain exceeds NRS 3, and these scores are recorded 
as well. In the recovery room, NRS scores are recorded, and 
in case of  an NRS >3, pain relief  is titrated with intravenous 
increments of  1-2 mg morphine or 1.5-3 mg piritramide un-
til the NRS is ≤3. At the orthopaedic ward, breakthrough 
pain (NRS >3) is treated with 5-10 mg oxycodone ad libitum 
or i.m./s.c. opioids if  oxycodone alone is not sufficient. Spo-
radically, tramadol is used when other opioids are not well 
tolerated. The distribution of  opioids on the recovery and or-
thopaedic ward is standardised. Opioids are checked, signed 
and registered in the patient data management system by two 
nurses at the time of  distribution. Patients are encouraged 
to mobilise starting on the day of  surgery according to our 
standard TKA protocol. Patients must fulfil functional criteria 
before discharge (Table 1).
Outcome measurements
The primary outcome parameter was the time to first request 
(TTFR) of  postoperative pain relief, defined as the time (in 
min) between ropivacaine infiltration and the first gift of  any 
opioid. Secondary outcomes included length of  hospital stay, 
transfusion requirements and the amount of  opioids admin-
istered during hospitalisation. Total opioid consumption was 
converted to intravenous morphine equivalent, using conver-
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sion factors of  0.67 for oral oxycodone (5), 0.7 for intravenous 
piritramide (6) and 0.05 for oral tramadol (5). An average 
NRS pain score at rest and during activity was calculated for 
each patient from all NRS scores recorded during hospitalisa-
tion; average pain scores per group are based on these indi-
vidual scores.
Sample size calculation and statistical analysis
Our null hypothesis was that the presence or absence of  a 
tourniquet would not result in differences in the TTFR. A 
difference of  180 min was selected as clinically relevant. Data 
gathered in our hospital for quality monitoring of  primary 
TKA without the use of  a tourniquet showed a standard devi-
ation of  561 min in the TTFR. Based on these data, the sam-
ple size required to identify a difference in TTFR of  at least 
180 min with a power of  80% was 300 patients per group 
(two-sided, level of  significance 0.05). Data analysis was per-
formed using Stata version 13.1 (Stata Corp., College Station, 
TX, USA). Shapiro-Wilk test was used for normal distribu-
tion of  data. Descriptive statistics of  patient and operation 
characteristics are presented as percentage (95% confidence 
interval), mean±SD or median and interquartile range (IQR, 
25th-75th percentile), as appropriate. Mann-Whitney U test 
was used to test the significant differences between the co-
horts, and chi-square test was used for numerical and categor-
ical variables, respectively. A p-value <0.05 was considered 
statistically significant. 
Results
All patients underwent surgery between December 2015 and 
March 2017. In this period, 108 patients underwent TKA un-
der general anaesthesia. These patients are not included in 
the cohorts. Patients in both cohorts had similar demographic 
and surgical characteristics (Table 2). In the tourniquet and 
non-tourniquet cohort, 31 and 27 patients respectively did 
not use a nonsteroidal anti inflammatory drug because of  an 
allergy or kidney insufficiency. All patients received parac-
etamol and gabapentin. There was no statistically significant 
difference in the TTFR between the two groups with a medi-
an (IQR) of  240 (102-651) min for group T versus 282 (100-
720) min for group NT (p=0.482).
Table 1. Functional discharge criteria
Active knee flexion ≥60°, passive knee extension 0°
Quadriceps muscle force ≥3 on the Medical Research Council 
Scale for muscle strength
Making independent transfers
Walking independently and safely with a walking aid
Climbing stairs independently and safely (if  necessary for home 
situation)
Table 2. Group characteristics
 Group T Group NT 
 (n=300) (n=300)
Sex, M/F 107/193 125/175
Age (year) 65 (6.7) 65 (9.3)
No. of  patients with age >60 years 212/300 221/300
No. of  patients not receiving  
etoricoxib* 31/300 27/300
Weight (kg) 86 (17.3) 87 (17.7)
Height (cm) 171 (10) 170 (13)
BMI (kg m−2) 28.9 (5.4) 29.2 (5.2)
Duration of  surgery, min 67 (15) 71 (13)
Tourniquet time 50 (44-60) n/a
Time from LIA to tourniquet  
deflation 13 (10-16) n/a
No. of  patients requiring RBC  
transfusion 3 4
Total units of  RBC transfused 5 7
*Due to allergy or kidney insufficiency. Data are presented as number 
of  patients, mean (SD) and median (25th-75th percentile). BMI: body 
mass index; n/a: not applicable; RBC: red blood cell; M: male; F: 
female
Table 3. Opioid consumption I
 Group T Group NT 
 (n=300) (n=300) p
TTFR 240 (102-651) 282 (100-720) 0.482
Total opioid  
consumption (mg in se) 38 (17-67) 27 (10-60) 0.014
Oxycodone  
consumption (mg in se) 33.5 (13.3-60.3) 26.8 (6.7-51.9) 0.012
Oxycodone  
consumption (mg) 50 (20-90) 40 (10-77.5)
Data are presented as median (25th-75th percentile). Total opioid con-
sumption is the sum of  oxycodone and tramadol consumption, and i.v., 
i.m. and s.c. opioids administration is converted to intravenous mor-
phine standard equivalent (se). Oxycodone consumption is presented 
as actual consumption (mg) and consumption converted to intravenous 
morphine standard equivalent (mg in se). TTFR: time to first request
Table 4. Opioid consumption II
 Group T Group NT 
 (n=300) (n=300) p
Use of  any opioid (%) 91.0 90.0 0.676 
 (87.2 to 93.7) (86.0 to 92.9)
Oxycodone use (%) 90.0 88.3 0.511 
 (86.0 to 92.9) (84.1 to 91.5)
Use of  total parenteral  24.0 23.3 0.848 
opioids (%) (19.5 to 29.2) (18.9 to 28.5)
Tramadol use (%) 3.0 (1.6 to 5.7) 3.3 (1.8 to 6.1) 0.816
Data are presented as percentage (95% CI) of  patients using postoper-
ative opioids
Turk J Anaesthesiol Reanim 2019; 47(2): 107-11 Bakker et al. Tourniquet and Opioids for Knee Arthroplasty
109
There was no difference in blood transfusion requirements 
between the groups (Table 2). Total opioid consumption (me-
dian (IQR)) was significantly higher in group T (37.5 (17-67) 
mg) than in group NT (27 (10-60) mg) (p=0.014). This dif-
ference was caused by a higher oxycodone consumption of  
patients in group T. There were no differences in parenteral 
opioid and tramadol consumption nor were there differences 
in the percentage of  patients using opioids. Tables 3 and 4 
summarise data on opioid consumption.
There were no differences between the groups in the average 
NRS pain scores at rest (median (IQR) 1.9 (1.4-2.5) for group 
T and 1.9 (1.3-2.5) for group NT) and during activity (median 
(IQR) 3.1 (2.4-3.7) for group T and 2.9 (2.3-3.5) for group NT).
There was no difference between group T and group NT in 
the median length of  hospital stay (median (IQR) 2 (2-3) and 
2 (2-3) days, respectively).
Discussion
The purpose of  the present study was to investigate the in-
fluence of  an intraoperative tourniquet on the duration of  
LIA as determined by the TTFR of  opioids. There was no 
difference in the TTFR between the two cohorts. Thus, our 
null hypothesis is retained. We found that the total opioid 
consumption was higher in patients in the tourniquet group. 
There was no difference in the length of  hospital stay.
The rationale for the use of  a pneumatic tourniquet during 
TKA is twofold: to limit intraoperative blood loss and to facili-
tate a bloodless surgical field. However, tourniquets are associ-
ated with several complications, such as deep venous thrombo-
sis, wound infections and delayed functional recovery caused by 
tissue ischaemia underneath and distal to the tourniquet (3, 4). 
Tourniquet use is also associated with increased postoperative 
pain. The first report describing the influence of  a tourniquet 
on postoperative pain after TKA was from 1995 (7). Several 
randomised controlled trials followed after the first study, with 
most of  them reaching the same conclusion that the use of  a 
tourniquet increases postoperative pain after TKA (8-12).
When using LIA, it stands to reason that the duration of  
analgesia will be affected by the absorption of  the LA from 
the site of  injection. Local blood flow is one of  the main de-
terminants of  systemic absorption (13). Previous studies in-
vestigating lidocaine plasma levels after intravenous region-
al anaesthesia demonstrate that prolonging the tourniquet 
time after injection slows down peak systemic absorption 
and lowers peak concentration (14). Likewise or similarly, 
compared with performing LIA without a tourniquet, the 
absence of  circulation at the site of  injection when perform-
ing LIA with an inflated tourniquet will delay the initial 
absorption. Whether this delay alters the pharmacokinetic 
profile sufficiently to exert an effect on the duration of  LIA 
is speculative; a delay in systemic absorption might result in 
an increased presence of  LA at the site of  injection, which 
might lengthen the duration of  analgesia. However, in the 
absence of  pharmacokinetic data, these contemplations re-
main hypothetical. We were unable to demonstrate an in-
creased duration of  analgesia in group T as determined by 
a difference in the TTFR, and under the conditions of  the 
present study, we conclude that the presence or absence of  a 
tourniquet does not affect the duration of  LIA.
Although the average NRS scores were similar, total opioid 
consumption was significantly higher in group T. Since there 
was no difference in the TTFR, it appears that in group T, post-
operative pain was more intense, requiring more opioids after 
the effect of  LIA had worn off. The most likely explanation for 
this observation is pain resulting from the tourniquet itself.
Our findings are in agreement with the study by Ejaz et al. (8) 
in which patients underwent TKA without LIA. In their study, 
patients in the tourniquet group had a higher opioid consump-
tion than those in the non-tourniquet group. Similar results were 
described by Abdel-Salam et al. (7) who reported an extended 
interval between opioid injections in the first 24 h after surgery in 
patients who underwent surgery without the use of  a tourniquet.
Although a femoral nerve block is still considered the gold 
standard procedure by many (15, 16), LIA is increasingly used 
for postoperative analgesia after TKA. LIA was introduced in 
2008 as a multimodal opioid-sparing technique for knee and 
hip surgery with the aim to achieve adequate analgesia with-
out motor impairment and with reduced opioid-related side 
effects, resulting in rapid recovery and reduced length of  hos-
pital stay (2). Although in different studies mixtures used for 
LIA vary in composition and in volume, two systematic reviews 
and meta-analyses have concluded that there are no significant 
differences in postoperative pain scores at rest and opioid con-
sumption between LIA and femoral nerve block (17, 18). Thus, 
with regard to postoperative pain relief, LIA appears to be an 
acceptable alternative for femoral nerve block.
Our study has several limitations. Although measuring postop-
erative pain scores is part of  our perioperative protocol and 
NRS scores are recorded regularly, the exact timing of  obtain-
ing these scores is not standardised, and the number of  pain 
scores recorded per patient may vary. Therefore, the average 
pain scores per group are less solid than a prospective analysis 
and should be interpreted with caution. However, since our pa-
tients are instructed to ask for pain relief  and our perioperative 
protocol ensures that patients are treated with opioids when the 
NRS pain score is >3, we believe that the difference in total 
opioid consumption combined with similar average pain scores 
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reliably reflects a difference in the intensity of  postoperative 
pain between the two groups, and that patients in group T need 
more opioids to establish adequate pain relief.
The second limitation of  our study is that we did not evalu-
ate the influence of  a tourniquet on the possible differences 
in short-term functional recovery between the two groups. 
However, since patients must meet a defined set of  functional 
criteria before discharge and we found no difference in the 
length of  hospital stay, we conclude that under the conditions 
of  this retrospective analysis, the use of  a tourniquet does not 
interfere with short-term functional recovery.
Conclusion
We found no difference in the TTFR after LIA for TKA with 
or without tourniquet, suggesting that the effect of  an inflated 
tourniquet during LA infiltration does not alter systemic ab-
sorption sufficiently to affect the duration of  analgesia. The 
use of  a tourniquet was associated with a higher total opioid 
consumption, which is most likely caused by pain resulting 
from the tourniquet itself.
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